Evidence map›Paper›PMID 37060529›Full record

ArticleClinical and experimental medicine2023

Pulmonary large cell neuroendocrine carcinoma (LCNEC): a population-based study addressing recent molecular-genetic advances and emerging therapeutic approaches.

Jaffar Khan, Abdul Qahar Khan Yasinzai, Sabrina Matosz, Marjan Khan, Saleh Heneidi, Hector Mesa, Aman Chauhan, Jaydira Del Rivero, Nagla Abdel Karim, Asad Ullah

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. [Advances of Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 2 countries.

Jaffar Khan *Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Abdul Qahar Khan Yasinzai *Bolan Medical College, Quetta, Pakistan.
Sabrina MatoszGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, 30912, USA.
Marjan KhanDepartment of Medicine, Marshfield Clinic, Marshfield, WI, USA.
Saleh HeneidiMolecular Pathology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Hector MesaDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Aman ChauhanDepartment of Hematology and Oncology, University of Kentucky, Lexington, USA.
Jaydira Del RiveroDivision of Hematology and Oncology, National Cancer Institute, NIH, Bethesda, MD, 20892, USA.
Nagla Abdel KarimInova Schar Cancer Institute, Department of Medicine, University of Virginia, Fairfax, VA, 22031, USA.
Asad UllahDepartment of Pathology and Laboratory Medicine, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, 37232, USA. drasadkhankakar@gmail.com.
Augusta University · USBolan Medical College · PKCedars-Sinai Medical Center · USIndiana University – Purdue University Indianapolis · USIndiana University School of MedicineMarshfield Clinic · USNational Cancer Institute · USUniversity of Kentucky · USUniversity of Virginia · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLarge cell neuroendocrine carcinoma (LCNEC) of the lung is a rare, aggressive cancer most commonly found in the lungs but not exclusively, with a worse prognosis than non-small cell lung carcinomas. Currently, LCNEC patients are treated using small cell and non-small cell protocols. This study aims to use the SEER database to identify demographic, clinical, pathological, and therapeutic factors affecting the prognosis and survival of patients with LCNEC of the lung.

methodsDemographic, clinical, and management data of patients with lung LCNEC were extracted from the SEER database for the period 2000-2018.

resultsIn the USA, LCNEC has a higher incidence in elderly white men: M:F ratio = 1.2:1, Caucasian: 83.3%, mean age: 67 ± 10.2 years. The most common treatment modality was chemotherapy only: 29.2%, followed by surgery: 21.5% (but in this group the statuses of chemotherapy were unknown), and combination surgery/chemotherapy: 8.8%. The overall and cause-specific 5-year survival was 17.5% (95% CI 16.3-18.8) and 21.9% (95% CI 20.5-23.4), respectively. By treatment, the best 5-year survival was for surgery alone (48%), followed by multimodality therapy (chemo + surgery + radiation) at 35% (95% CI 27-43). Age > 60 years, male gender, size > 7 cm, and nodal and liver metastasis were independent risk factors associated with increased mortality.

conclusionLung LCNEC is an aggressive neoplasm most common in older white males that presents at an advanced stage despite small primary tumors. Most patients die within 2 years. The best predictor of survival is surgery with chemotherapy. Given its dismal prognosis, new treatment guidelines are needed for this aggressive cancer.

Indexed as

Carcinoma, Large CellCarcinoma, NeuroendocrineCarcinoma, Non-Small-Cell LungLung NeoplasmsAgedHumansMaleMiddle AgedPrognosisHigh-grade neuroendocrineLarge cell neuroendocrine carcinomaLung cancerMolecularPrimary pulmonarySmall cell

Identifiers

PMID37060529
OpenAlexW4365811121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.